Literature DB >> 19372170

Temporal effects of antibiotic use and Clostridium difficile infections.

Nathalie Vernaz1, Kirsteen Hill, Stephanie Leggeat, Dilip Nathwani, Gabby Philips, Pascal Bonnabry, Peter Davey.   

Abstract

OBJECTIVES: We tested a previously published model for the analysis of the temporal relationship between antibiotic use and the incidence of Clostridium difficile infection in a hospital with stable incidence of infection at >1 case per 1000 admissions per month.
METHODS: The study period was from April 2004 to June 2008 and used data from Infection Control and Hospital Pharmacy. We first described the monthly variation in C. difficile infection and then constructed a multivariate transfer function model that included lag time (cases of C. difficile infection in previous months and delays between changes in antibiotic use and changes in C. difficile infection).
RESULTS: The average incidence of C. difficile infection was 1.5 cases per 1000 patients per month with no significant increase over 3 years. The number of cases of C. difficile infection in 1 month was dependent on the average number of cases of C. difficile infection in the previous 2 months. The models with data from the whole hospital showed a statistically significant relationship between the number of both hospital-acquired C. difficile infections and total C. difficile infections and consumption of piperacillin/tazobactam, ciprofloxacin and cefuroxime. The association between C. difficile infection and consumption of co-amoxiclav was only significant for hospital-acquired C. difficile infection. The model for hospital-acquired C. difficile infections explained 61% of the variance in C. difficile infections.
CONCLUSIONS: These results provide support for antibiotic policies that minimize the use of broad-spectrum penicillins (co-amoxiclav and piperacillin/tazobactam), cephalosporins and fluoroquinolones.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19372170     DOI: 10.1093/jac/dkp128

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  13 in total

1.  Antimicrobial stewardship.

Authors:  Shira Doron; Lisa E Davidson
Journal:  Mayo Clin Proc       Date:  2011-11       Impact factor: 7.616

Review 2.  Origins and evolution of antibiotic resistance.

Authors:  Julian Davies; Dorothy Davies
Journal:  Microbiol Mol Biol Rev       Date:  2010-09       Impact factor: 11.056

3.  Clostridium difficile PCR Ribotype 018, a Successful Epidemic Genotype.

Authors:  Rossella Baldan; Alberto Trovato; Valentina Bianchini; Anna Biancardi; Paola Cichero; Maria Mazzotti; Paola Nizzero; Matteo Moro; Cristina Ossi; Paolo Scarpellini; Daniela Maria Cirillo
Journal:  J Clin Microbiol       Date:  2015-06-03       Impact factor: 5.948

4.  Second generation cephalosporin antibiotic prophylaxis and Clostridium difficile infection in hip and knee arthroplasty.

Authors:  K Al-Tawil; A Babu; M Loeffler; T Williams
Journal:  Ann R Coll Surg Engl       Date:  2017-05       Impact factor: 1.891

5.  Association between Clostridium difficile infection and antimicrobial usage in a large group of English hospitals.

Authors:  Joao B Pereira; Tracey M Farragher; Mary P Tully; Jonathan Jonathan Cooke
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

6.  Benefits of Adding a Rapid PCR-Based Blood Culture Identification Panel to an Established Antimicrobial Stewardship Program.

Authors:  Shawn H MacVane; Frederick S Nolte
Journal:  J Clin Microbiol       Date:  2016-08-03       Impact factor: 5.948

7.  Stronger correlation between antibiotic use and the incidence of Clostridium difficile determined by culture results instead of faecal toxin detection only.

Authors:  D Mertz; R Frei; H Plagge; M Battegay; A F Widmer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-08-13       Impact factor: 3.267

8.  A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections.

Authors:  Inge C Gyssens; Matthew Dryden; Peter Kujath; Dilip Nathwani; Nicolaas Schaper; Barbara Hampel; Peter Reimnitz; Jeff Alder; Pierre Arvis
Journal:  J Antimicrob Chemother       Date:  2011-09-06       Impact factor: 5.790

9.  Amoxicillin plus temocillin as an alternative empiric therapy for the treatment of severe hospital-acquired pneumonia: results from a retrospective audit.

Authors:  H Habayeb; B Sajin; K Patel; C Grundy; A Al-Dujaili; S Van de Velde
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-05-19       Impact factor: 3.267

10.  Nosocomial transmission of C. difficile in English hospitals from patients with symptomatic infection.

Authors:  Esther van Kleef; Antonio Gasparrini; Rebecca Guy; Barry Cookson; Russell Hope; Mark Jit; Julie V Robotham; Sarah R Deeny; W John Edmunds
Journal:  PLoS One       Date:  2014-06-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.